Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Rs one crore for each district to create medicine pool and support Centre of Excellence for Telemedicine
Lenalidomide is used to treat cancer and also some anaemia disorders
The project is a collaboration between IIT Delhi and AIIMS
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
The group has a total of 320 ANDA approvals
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Subscribe To Our Newsletter & Stay Updated
